Cerundolo Vincenzo, Silk Jonathan D, Masri S Hajar, Salio Mariolina
Tumour Immunology Group, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, OX3 9DU, UK.
Nat Rev Immunol. 2009 Jan;9(1):28-38. doi: 10.1038/nri2451.
To optimize vaccination strategies, it is important to use protocols that can 'jump-start' immune responses by harnessing cells of the innate immune system to assist the expansion of antigen-specific B and T cells. In this Review, we discuss the evidence indicating that invariant natural killer T (iNKT) cells can positively modulate dendritic cells and B cells, and that their pharmacological activation in the presence of antigenic proteins can enhance antigen-specific B- and T-cell responses. In addition, we describe structural and kinetic analyses that assist in the design of optimal iNKT-cell agonists that could be used in the clinical setting as vaccine adjuvants.
为优化疫苗接种策略，采用能够通过利用先天免疫系统细胞来“启动”免疫反应，从而辅助抗原特异性B细胞和T细胞扩增的方案至关重要。在本综述中，我们讨论了相关证据，这些证据表明不变自然杀伤T（iNKT）细胞可正向调节树突状细胞和B细胞，并且在存在抗原性蛋白质的情况下对其进行药理学激活可增强抗原特异性B细胞和T细胞反应。此外，我们还描述了有助于设计最佳iNKT细胞激动剂的结构和动力学分析，这些激动剂可在临床环境中用作疫苗佐剂。
